- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, July 13, 2018
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
The National Pharmaceutical Council’s Tuesday CER Daily Newsfeed highlighted an article from The American Journal of Managed Care® (AJMC®). The article, “VBID Strategies to Encourage Drug Adherence Working, Review Finds,” covered an updated review of value-based insurance design as a strategy for increasing consumer adherence to prescription medications. The review found moderate-quality evidence that such strategies are useful for increasing the use of high-value drug classes while lowering cost sharing.
Leader-Telegram's article on food as medicine included a study published in the June issue of AJMC®, “Simply Delivered Meals: A Tale of Collaboration.” The study put a spotlight on the growing recognition of the importance of social determinants of health and assessed the impact of a specialized meal delivery program called Simply Delivered for ME. The study found that the meal service, which was offered to patients in a community-based care transition program, was associated with cost savings and a 38% reduction in the 30-day hospital readmission rate.
Allergies and Asthma Prevalence Rise With Climate Change Extremes and Pollutants
June 30th 2025Increasing environmental events driven by climate change and human activity exacerbate allergy and asthma conditions, further compounded by exposure to persistent pollutants like per-and polyfluoroalkyl substances and microplastics.
Read More
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
MRD-Guided Ibrutinib Plus Venetoclax Effective in R/R CLL
June 30th 2025Patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL) had similar results when they continued on ibrutinib or stopped and started ibrutinib plus venetoclax based on minimal residual disease (MRD) status.
Read More
